Search | Clinical Trials Finder

Conditions: Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Ovarian Carcinoma
Interventions: Everolimus, Laboratory Biomarker Analysis, Letrozole; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Digestive System Neuroendocrine Tumor G2
Interventions: Biospecimen Collection, Cabozantinib, Computed Tomography, Everolimus, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Sunitinib; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 34
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 26 more

Conditions: Lymphocytic Leukemia
Interventions: alemtuzumab, everolimus; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Kidney Transplantation
Interventions: Certican; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Week to 16 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Advanced Malignant Solid Neoplasm, Estrogen Receptor Positive, HER2/Neu Positive, Postmenopausal, Premenopausal, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Refractory Breast Carcinoma, Refractory Hormone Receptor Positive Breast Carcinoma, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Everolimus, Laboratory Biomarker Analysis, Letrozole, Trastuzumab; Drug · Other · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 5
States / cities: Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more

Conditions: Advanced Malignant Solid Neoplasm
Interventions: Adavosertib, Carboplatin, Everolimus, Temozolomide, Trametinib, Veliparib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 8
States / cities: Aurora, Colorado • Atlanta, Georgia • Lexington, Kentucky + 5 more

Conditions: Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor G1, Lung Neuroendocrine Tumor G2, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Non-Functioning Lung Neuroendocrine Tumor, Recurrent Lung Neuroendocrine Neoplasm, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Lung Neuroendocrine Tumor
Interventions: Biospecimen Collection, Computed Tomography, Everolimus, Fludeoxyglucose F-18, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Survey Administration; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 29
States / cities: Birmingham, Alabama • Beverly Hills, California • Loma Linda, California + 24 more

Conditions: Atypical Endometrial Hyperplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Interventions: Everolimus, Laboratory Biomarker Analysis, Levonorgestrel-Releasing Intrauterine System; Drug · Other · Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 18
States / cities: Greeley, Colorado • Loveland, Colorado • Honolulu, Hawaii + 11 more

Conditions: Kidney Neoplasms, Kidney (Renal Cell) Cancer
Interventions: Everolimus, Bevacizumab; Drug
Lead sponsor: Sandy Srinivas; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis, Renal Replacement Therapy, Renal Transplantation
Interventions: Induction therapy, Corticosteroids, EVR+rCNI, MPA+sCNI; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 2,037 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 40
States / cities: Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 32 more

Conditions: ALK Positive, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, ROS1 Gene Rearrangement, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions: Ceritinib, Everolimus, Laboratory Biomarker Analysis, Pharmacological Study; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Heart Transplantation
Interventions: Everolimus (Certican); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 12
States / cities: Birmingham, Alabama • Los Angeles, California • Tampa, Florida + 7 more

Conditions: Small Cell Lung Cancer
Interventions: RAD001 (everolimus); Drug
Lead sponsor: Ahmad Tarhini; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 19
States / cities: Steubenville, Ohio • Beaver, Pennsylvania • Clairton, Pennsylvania + 11 more

Conditions: Adult Diffuse Astrocytoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Subependymal Giant Cell Astrocytoma, Recurrent Adult Brain Neoplasm
Interventions: Everolimus, Archival Tissue Analysis; Drug · Other
Lead sponsor: Susan Chang; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma, High-Grade Glioma (HGG)
Interventions: Everolimus, Trametinib; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 1 Year to 25 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more

Conditions: Recurrent Childhood Brain Tumor
Interventions: Tumor biology testing, Temozolomide, Etoposide, Sorafenib, Everolimus, Erlotinib, Dasatinib; Device · Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 1 Month to 30 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: High Model for End-Stage Liver Disease (MELD) Score
Interventions: Everolimus, Myfortic and Tacrolimus, Myfortic and Tacrolimus; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Salivary Gland Dysfunction, Xerostomia, Head and Neck Cancer
Interventions: Everolimus, Laboratory Biomarker Analysis, Survey Administration; Drug · Other
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Breast Cancer
Interventions: Carboplatin, Everolimus; Drug
Lead sponsor: Amy Tiersten; Other
Eligibility: 18 Years and older · Female only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 3
States / cities: New York, New York

Conditions: Liver Transplant Recipient
Interventions: Tacrolimus (reduced tacrolimus), Everolimus (reduced tacrolimus), Tacrolimus (tacrolimus elimination), Everolimus (tacrolimus elimination), Tacrolimus (tacrolimus control), Corticosteroids; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 20 Years to 75 Years
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 15
States / cities: Washington D.C., District of Columbia • Tampa, Florida • Lexington, Kentucky + 10 more

Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Bevacizumab, Everolimus, Laboratory Biomarker Analysis, Placebo; Biological · Drug · Other
Lead sponsor: GOG Foundation; Network
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 45
States / cities: Phoenix, Arizona • Burbank, California • Los Angeles, California + 32 more

Conditions: CNS Embryonal Tumor, Not Otherwise Specified, Malignant Glioma, Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Childhood Ependymoma, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma, Refractory Diffuse Intrinsic Pontine Glioma
Interventions: Everolimus, Laboratory Biomarker Analysis, Pharmacological Study, Ribociclib; Drug · Other
Lead sponsor: Pediatric Brain Tumor Consortium; Network
Eligibility: 1 Year to 21 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 12
States / cities: Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more

Conditions: Breast Cancer
Interventions: Capecitabine, RAD001; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Stanford, California

Conditions: Metastatic Kidney Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
Interventions: Akt Inhibitor MK2206, Everolimus, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 8
States / cities: Beverly Hills, California • Duarte, California • Los Angeles, California + 5 more

Search by objective public record fields.

Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer

Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)

Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

A Study of Safety, Tolerability & Efficacy of Certican in de Novo Heart Transplant (Tx) Patients

Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer

Everolimus in Treating Patients With Recurrent Low-Grade Glioma

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors

Myfortic in High MELD Liver Transplantation

Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy

Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer

Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients

Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors

Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast

Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer